title: Beneficial effect of adjuvant tamoxifen therapy in primary breast cancer patients with high oestrogen receptor values.
abstract: Oestrogen receptor concentrations were measured in primary tumours of 291 postmenopausal breast cancer patients with high risk of recurrence. These patients were a subset of the 1650 patients participating in the Danish Breast Cancer Cooperative Group's trial of adjuvant treatment with tamoxifen (30 mg daily for one year). A cut-off point of 10 fmol/mg cytosol protein and the use of a Cox proportional hazards model distinguished between patients with long recurrence-free survivals and those with early recurrent disease. The use of this model also showed that patients with an oestrogen-receptor content below 100 fmol/mg did not benefit from the endocrine therapy, while those with concentrations above 100 fmol/mg had a significantly longer recurrence-free survival. This finding is consistent with the response of advanced breast cancer to endocrine treatment.
authors.forename: C
authors.initials: C
authors.lastname: Rose
authors.forename: S M
authors.initials: SM
authors.lastname: Thorpe
authors.forename: K W
authors.initials: KW
authors.lastname: Andersen
authors.forename: B V
authors.initials: BV
authors.lastname: Pedersen
authors.forename: H T
authors.initials: HT
authors.lastname: Mouridsen
authors.forename: M
authors.initials: M
authors.lastname: Blichert-Toft
authors.forename: B B
authors.initials: BB
authors.lastname: Rasmussen
mesh_terms: D000368:Aged; D001943:Breast Neoplasms / Q000032:analysis / Q000188:drug therapy* / Q000473:pathology; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008207:Lymphatic Metastasis; D008593:Menopause; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D009376:Neoplasms, Hormone-Dependent / Q000188:drug therapy; D011960:Receptors, Estrogen / Q000032:analysis*; D012306:Risk; D013629:Tamoxifen / Q000627:therapeutic use*
chemical_list: D011960:Receptors, Estrogen; D013629:Tamoxifen